**Core Concept**
Denosumab is a human monoclonal antibody that targets RANKL, a protein essential for osteoclast formation and activation. By inhibiting RANKL, denosumab decreases bone resorption and increases bone density.

**Why the Correct Answer is Right**
Denosumab is specifically indicated for the treatment of osteoporosis in postmenopausal women and men at high risk of fracture. The drug's mechanism of action involves binding to RANKL on the surface of osteoclasts and their precursors, thereby preventing their activation and subsequent bone resorption. This leads to an increase in bone mineral density and a reduction in the risk of fractures.

**Why Each Wrong Option is Incorrect**
**Option A:** Osteomalacia is a condition characterized by softening of the bones due to impaired mineralization, typically resulting from vitamin D deficiency or phosphate deficiency. Denosumab is not indicated for osteomalacia as it does not address the underlying issue of mineralization.
**Option B:** Osteoarthritis is a degenerative joint disease characterized by cartilage breakdown and inflammation. Denosumab is not used to treat osteoarthritis, as its mechanism of action is focused on bone resorption rather than joint inflammation or cartilage degradation.
**Option D:** Osteosarcoma is a type of bone cancer that arises from osteoid tissue. While denosumab may be used in the management of bone metastases from solid tumors, it is not specifically indicated for the treatment of osteosarcoma.

**Clinical Pearl / High-Yield Fact**
Denosumab is also used in the treatment of giant cell tumor of bone, a rare benign tumor that can cause bone destruction. This highlights the drug's ability to inhibit osteoclast activity and prevent bone resorption in various conditions.

**✓ Correct Answer: C. Osteoporosis. Denosumab is used in the treatment of osteoporosis.**